Horizon Pharma (NASDAQ:HZNP) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Several other analysts have also issued reports on the stock. Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and raised their price target for the stock from $12.00 to $18.00 in a research report on Friday, January 12th. ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Morgan Stanley raised their price target on shares of Horizon Pharma from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Friday, March 2nd. Finally, UBS set a $20.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $18.64.
NASDAQ:HZNP opened at $13.65 on Friday. Horizon Pharma has a 1 year low of $9.45 and a 1 year high of $16.02. The company has a current ratio of 1.63, a quick ratio of 1.54 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $2,306.36, a P/E ratio of 11.57, a PEG ratio of 0.59 and a beta of 1.24.
Large investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd bought a new position in shares of Horizon Pharma during the 4th quarter worth about $160,000. K2 Principal Fund L.P. lifted its holdings in shares of Horizon Pharma by 126.1% during the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 53,574 shares during the period. Zeke Capital Advisors LLC bought a new position in shares of Horizon Pharma during the 4th quarter worth about $167,000. Brown Advisory Inc. bought a new position in shares of Horizon Pharma during the 3rd quarter worth about $145,000. Finally, Investors Research Corp bought a new position in shares of Horizon Pharma during the 4th quarter worth about $174,000. 86.75% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3336831/bidaskclub-downgrades-horizon-pharma-hznp-to-sell.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.